benzinga.com
Dow Dips 200 Points; Q32 Bio Shares Jump
U.S. stocks traded lower this morning, with the Dow Jones falling around 200 points on Monday.
Q32 Bio Inc.QTTBNASDAQ
LOADING
|||
Latest News
Loading news...
benzinga.com
Why Is Small-Cap Q32 Bio Stock Soaring On Monday?
Q32 Bio Inc. (NASDAQ: QTTB) stock is trading higher on Monday, with a session volume of 70.56 million compared to the average volume of 217.704 thousand as per data from Benzinga Pro.
prnewswire.com
Q32 Bio Sells Complement Inhibitor ADX-097
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments upon achievement of certain development, regulatory and commercial milestones and eligible for tiered royalties up to a mid-teen percent of annual net sales -- -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these programs -- WALTHAM, Mass. , Dec. 1, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (NASDAQ: AKBA) ("Akebia").
prnewswire.com
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected in mid-2026 -- -- Dosing of patients in Part A open-label extension (OLE) ongoing -- -- Cash and cash equivalents of $49.0 million as of September 30, 2025 expected to provide financial runway into 2027 -- WALTHAM, Mass. , Nov. 13, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended September 30, 2025, and provided recent corporate updates.
prnewswire.com
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass. , Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has completed enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA.
prnewswire.com
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
WALTHAM, Mass. , Aug. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 3:45 p.m.
fool.com
Q32 Bio (QTTB) Q2 Loss Drops 45%
Q32 Bio (QTTB) Q2 Loss Drops 45%
prnewswire.com
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 -- -- Strengthened leadership team with appointment of Adrien Sipos, M.D., Ph.D., an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, as Interim Chief Medical Officer -- -- Cash and cash equivalents of $54.8 million as of June 30, 2025, which is now expected to provide financial runway into 2027 -- WALTHAM, Mass.
prnewswire.com
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
-- Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience -- WALTHAM, Mass. , June 25, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the appointment of Adrien Sipos, M.D.
https://www.defenseworld.net
19,009 Shares in Q32 Bio Inc. (NASDAQ:QTTB) Acquired by Squarepoint Ops LLC
Squarepoint Ops LLC bought a new position in shares of Q32 Bio Inc. (NASDAQ:QTTB – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 19,009 shares of the company’s stock, valued at approximately $65,000. Squarepoint Ops LLC owned about 0.16% of Q32 Bio as of its most recent SEC filing. A number of other institutional investors and hedge funds also recently added to or reduced their stakes in QTTB. Rhumbline Advisers grew its holdings in Q32 Bio by 1,164.3% during the fourth quarter. Rhumbline Advisers now owns 105,544 shares of the company’s stock worth $363,000 after acquiring an additional 97,196 shares during the period. Bleakley Financial Group LLC acquired a new stake in shares of Q32 Bio during the fourth quarter valued at $149,000. Raymond James Financial Inc. acquired a new stake in shares of Q32 Bio during the fourth quarter valued at $37,000. Cubist Systematic Strategies LLC purchased a new position in Q32 Bio during the fourth quarter worth about $42,000. Finally, Deutsche Bank AG lifted its position in Q32 Bio by 699.8% during the fourth quarter. Deutsche Bank AG now owns 25,018 shares of the company’s stock worth $86,000 after buying an additional 21,890 shares during the period. Hedge funds and other institutional investors own 31.32% of the company’s stock. Analyst Ratings Changes A number of equities analysts have recently commented on the company. Piper Sandler downgraded Q32 Bio from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $20.00 to $4.00 in a report on Tuesday, February 11th. BMO Capital Markets downgraded Q32 Bio from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $22.00 to $3.00 in a report on Tuesday, February 11th. Finally, Wells Fargo & Company cut their price objective on Q32 Bio from $16.00 to $15.00 and set an “equal weight” rating on the stock in a report on Wednesday, March 12th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $24.71. Read Our Latest Report on QTTB Q32 Bio Price Performance Shares of NASDAQ:QTTB opened at $1.68 on Wednesday. Q32 Bio Inc. has a fifty-two week low of $1.38 and a fifty-two week high of $53.79. The business has a 50-day moving average of $1.75 and a two-hundred day moving average of $4.33. The stock has a market capitalization of $20.49 million, a P/E ratio of -0.12 and a beta of -0.03. The company has a debt-to-equity ratio of 0.61, a current ratio of 6.53 and a quick ratio of 6.53. Q32 Bio (NASDAQ:QTTB – Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.23) by $0.33. On average, equities research analysts predict that Q32 Bio Inc. will post -12.32 EPS for the current fiscal year. Q32 Bio Company Profile (Free Report) Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. See Also Five stocks we like better than Q32 Bio Quiet Period Expirations Explained AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway What is a Dividend Harvesting Strategy and How Can Investors Profit from it? Casey’s Surges on Strong Q4, More Gains Likely Ahead What is a Secondary Public Offering? What Investors Need to Know Government Mandate Sends eVTOL Stocks Flying
prnewswire.com
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
-- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 -- -- First patient dosed in SIGNAL-AA Part A open-label extension (OLE) -- -- Fast Track designation (FTD) granted to bempikibart for the treatment of alopecia areata (AA); SIGNAL-AA Part A results presented as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting -- -- Cash and cash equivalents of $65.5 million as of March 31, 2025 expected to provide financial runway into 2H'26 -- WALTHAM, Mass. , May 8, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended March 31, 2025, and provided recent corporate updates.
prnewswire.com
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
WALTHAM, Mass. , April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that the United States Food and Drug Administration ("FDA") has granted Fast Track designation (FTD) to Q32 Bio's bempikibart (ADX-914) for the treatment of AA.
prnewswire.com
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
-- SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass. , April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced that the Company has dosed the first patients in both the Part A open-label extension (OLE) and Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with alopecia areata (AA).
zacks.com
All You Need to Know About Q32 Bio (QTTB) Rating Upgrade to Buy
Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
prnewswire.com
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting -- -- Advancing bempikibart in patients with AA, with SIGNAL-AA open-label extension (OLE) and SIGNAL-AA Part B on track to dose patients in 1H'25; SIGNAL-AA Part B topline data on-track for 1H'26 -- -- Cash and cash equivalents of $78.0 million as of December 31, 2024 expected to provide financial runway into 2H'26 -- WALTHAM, Mass. , March 11, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the quarter ended December 31, 2024, and provided recent corporate updates.
prnewswire.com
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata (AA) -- -- Durable, ongoing responses in multiple patients through week 36 follow-up period and beyond to week 55, despite only 24 weeks of dosing, suggestive of potential for remittive effect; multiple inbound patient requests to re-initiate dosing -- -- In the Phase 2a clinical trial, bempikibart was observed to be safe and well-tolerated, with PK supporting subcutaneous dosing and receptor occupancy data demonstrating desired target engagement; clinical biomarkers showed changes in Th2 biomarkers, and expected on-mechanism changes in T-cells, indicative of potent IL-7 and TSLP inhibition -- -- Bempikibart development program remains on track with open-label extension study to initiate in 1H'25; SIGNAL-AA Part B remains on track for initiation of dosing in 1H'25, with topline data expected in 1H'26 -- WALTHAM, Mass. , March 8, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) at the 2025 American Academy of Dermatology (AAD) Meeting in Orlando, FL.
prnewswire.com
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata (AA) -- WALTHAM, Mass. , Feb. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) will be presented in a late-breaking oral session at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place March 7-11 in Orlando, FL.
prnewswire.com
Q32 Bio to Participate in Upcoming March Investor Conferences
WALTHAM, Mass. , Feb. 26, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in two upcoming investor conferences in March: TD Cowen 45th Annual Health Care Conference Date: Wednesday, March 5, 2025 Presentation Time: 11:50 a.m.
prnewswire.com
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
-- Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating open-label extension in 1H'25; SIGNAL-AA Part B remains on track for initiation of dosing in 1H'25, with topline data expected in 1H'26 -- -- Company to discontinue renal basket trial for ADX-097 to conserve resources and evaluate strategic options for its tissue-targeted complement inhibitor platform -- -- Cash runway expected to extend to 2H'26 -- WALTHAM, Mass. , Feb. 10, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced a corporate restructuring to focus on the advancement of its bempikibart clinical development program for the treatment of patients with alopecia areata (AA).
prnewswire.com
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
WALTHAM, Mass. , Feb. 4, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in a virtual company presentation at 4:00 p.m.